Eribulin Mesylate Injection 1 mg/2 mL (0.5 mg/mL) Single-Dose Vial 2 mL (RX)Eribulin Mesylate Injection 1 mg 2 mL (0. 5 mg mL) is an FDA approved, cutting edge antineoplastic agent used in the treatment of metastatic breast cancer and unresectable or metastatic liposarcoma. This single dose, sterile, 2 mL vial delivers precise dosing and reliable administration in hospital, infusion center, and oncology clinic settings. Eribulin Mesylate is a synthetic analog of halichondrin B, proven to extend survival in patients with